Patents Assigned to Neuralab Limited
-
Patent number: 6913745Abstract: Disclosed are pharmaceutical compositions and methods for preventing or treating a number of amyloid diseases, including Alzheimer's disease, prion diseases, familial amyloid neuropathies and the like. The pharmaceutical compositions include immunologically reactive amounts of amyloid fibril components, particularly fibril-forming peptides or proteins. Also disclosed are therapeutic compositions and methods which use immune reagents that react with such fibril components.Type: GrantFiled: June 1, 2000Date of Patent: July 5, 2005Assignee: Neuralab LimitedInventor: Dale B. Schenk
-
Publication number: 20050142132Abstract: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A? in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease. Preferred agents including N-terminal fragments of A? and antibodies binding to the same.Type: ApplicationFiled: February 14, 2005Publication date: June 30, 2005Applicant: Neuralab LimitedInventors: Dale Schenk, Frederique Bard, Theodore Yednock
-
Patent number: 6905686Abstract: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A? in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease. Preferred agents including N-terminal fragments of A? and antibodies binding to the same.Type: GrantFiled: November 28, 2000Date of Patent: June 14, 2005Assignee: Neuralab LimitedInventor: Dale B. Schenk
-
Publication number: 20050123544Abstract: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A? in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease. Preferred agents including N-terminal fragments of A? and antibodies binding to the same.Type: ApplicationFiled: November 24, 2004Publication date: June 9, 2005Applicant: Neuralab LimitedInventors: Dale Schenk, Frederique Bard, Theodore Yednock
-
Publication number: 20050118651Abstract: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A? in the brain of a patient. Preferred agents include antibodies, e.g., humanized antibodies.Type: ApplicationFiled: June 1, 2004Publication date: June 2, 2005Applicants: Neuralab Limited, WyethInventors: Guriq Basi, Jose Saldanha, Frederique Bard
-
Patent number: 6890535Abstract: Disclosed are pharmaceutical compositions and methods for preventing or treating a number of amyloid diseases, including Alzheimer's disesase, prion diseases, familial amyloid neuropathies and the like. The pharmaceutical compositions include immunologically reactive amounts of amyloid fibril components, particularly fibril-forming peptides or proteins. Also disclosed are therapeutic compositions and methods which use immune reagents that react with such fibril components.Type: GrantFiled: November 28, 2000Date of Patent: May 10, 2005Assignee: Neuralab LimitedInventor: Dale B. Schenk
-
Patent number: 6875434Abstract: Disclosed are pharmaceutical compositions and methods for preventing or treating a number of amyloid diseases, including Alzheimer's disesase, prion diseases, familial amyloid neuropathies and the like. The pharmaceutical compositions include immunologically reactive amounts of amyloid fibril components, particularly fibril-forming peptides or proteins. Also disclosed are therapeutic compositions and methods which use immune reagents that react with such fibril components.Type: GrantFiled: November 28, 2000Date of Patent: April 5, 2005Assignee: Neuralab LimitedInventor: Dale B. Schenk
-
Publication number: 20050059591Abstract: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A? in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease. Preferred agents including N-terminal fragments of A? and antibodies binding to the same.Type: ApplicationFiled: April 12, 2004Publication date: March 17, 2005Applicant: Neuralab LimitedInventors: Dale Schenk, Nicki Vasquez, Theodore Yednock
-
Patent number: 6866850Abstract: The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A? peptide or an antibody thereto.Type: GrantFiled: March 31, 2004Date of Patent: March 15, 2005Assignee: Neuralab LimitedInventor: Dale B. Schenk
-
Patent number: 6866849Abstract: The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A? peptide or an antibody thereto.Type: GrantFiled: March 31, 2004Date of Patent: March 15, 2005Assignee: Neuralab LimitedInventor: Dale B. Schenk
-
Publication number: 20050053614Abstract: The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A? peptide or an antibody thereto.Type: ApplicationFiled: July 1, 2004Publication date: March 10, 2005Applicant: Neuralab LimitedInventor: Dale Schenk
-
Publication number: 20050048049Abstract: The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A? peptide, active fragments thereof or an antibody thereto.Type: ApplicationFiled: August 20, 2004Publication date: March 3, 2005Applicant: Neuralab LimitedInventor: Dale Schenk
-
Publication number: 20050037026Abstract: The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A? peptide or an antibody thereto.Type: ApplicationFiled: September 2, 2004Publication date: February 17, 2005Applicant: Neuralab LimitedInventor: Dale Schenk
-
Publication number: 20050031629Abstract: The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A? peptide or an antibody thereto.Type: ApplicationFiled: March 31, 2004Publication date: February 10, 2005Applicant: Neuralab LimitedInventor: Dale Schenk
-
Publication number: 20050019343Abstract: The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A? peptide or an antibody thereto.Type: ApplicationFiled: September 2, 2004Publication date: January 27, 2005Applicant: Neuralab LimitedInventor: Dale Schenk
-
Publication number: 20050019330Abstract: The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A? peptide, active fragments thereof or an antibody thereto.Type: ApplicationFiled: August 20, 2004Publication date: January 27, 2005Applicant: Neuralab LimitedInventor: Dale Schenk
-
Publication number: 20050019328Abstract: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A? in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease. Preferred agents including N-terminal fragments of A? and antibodies binding to the same.Type: ApplicationFiled: April 12, 2004Publication date: January 27, 2005Applicant: Neuralab LimitedInventor: Dale Schenk
-
Publication number: 20050013815Abstract: The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A? peptide, active fragments thereof or an antibody thereto.Type: ApplicationFiled: August 20, 2004Publication date: January 20, 2005Applicant: Neuralab LimitedInventor: Dale Schenk
-
Publication number: 20040265308Abstract: The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A&bgr; peptide, active fragments thereof or an antibody thereto.Type: ApplicationFiled: February 27, 2004Publication date: December 30, 2004Applicant: Neuralab LimitedInventor: Dale B. Schenk
-
Publication number: 20040265301Abstract: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A&bgr; in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease. Preferred agents including N-terminal fragments of A&bgr; and antibodies binding to the same.Type: ApplicationFiled: July 12, 2004Publication date: December 30, 2004Applicant: Neuralab LimitedInventors: Dale B. Schenk, Frederique Bard, Theodore Yednock
